Apr 18, 2025, 14:07 | Blog

Humaid Al-Shamsi: Burjeel Cancer Institute signed an MoU with the European Institute of Oncology

Humaid Al-Shamsi, Founder and Director of Medical Oncology at Burjeel Medical City, shared a post…

Apr 14, 2025, 22:12 | Insight

Lorenzo Guidi: Bispecific Antibodies in Hematologic and Solid Tumors

Lorenzo Guidi, Medical Oncology Resident at the European Institute of Oncology (IEO), shared a post…

Apr 9, 2025, 08:51 | Drugs

Elvina Almuradova: Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Elvina Almuradova, Ambassador at European School of Oncology, shared an article Komal Jhaveri and her…

Apr 9, 2025, 07:16 | Blog

Vivek Subbiah: Key Recommendations for structuring Molecular Tumour Boards in clinical practice

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a LinkedIn post…

Apr 8, 2025, 15:46 | Science

Vivek Subbiah: Exploring the role of ctDNA Clearance as a Predictive Biomarker in Solid Tumors

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…

Apr 8, 2025, 07:38 | Blog

Giuseppe Curigliano: ESMO Recommendations on Molecular Tumour Boards in Clinical Practice

Giuseppe Curigliano, Member of the Editorial Board for OncoDaily and President Elect of ESMO, posted…

Apr 7, 2025, 09:29 | Blog

Giuseppe Curigliano: ESMO Precision Oncology Working Group Quality and Structure Recommendations for MTBs

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, shared a LinkedIn post about recent…

Mar 16, 2025, 11:59 | Blog

SGBCC 2025 Highlights by Paolo Tarantino

The 19th St. Gallen International Breast Cancer Conference (SGBCC) took place from March 12–15, 2025,…

Mar 4, 2025, 07:35 | Blog

DESTINY-Breast07 phase Ib/II trial presented at ESMO TAT 2025

ESMO posted on LinkedIn: "Updated results presented at ESMO TAT 2025 from the DESTINY-Breast07 phase…

Feb 21, 2025, 10:55 | Blog

Giuseppe Curigliano: Mourning the untimely passing of Giovanni Scambia - a visionary leader in European gynecologic oncology

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, posted on LinkedIn: "We mourn the…

Feb 18, 2025, 07:54 | Blog

Giuseppe Curigliano: Maurizio Scaltriti - one of the most transformative oncologists of the last 30 years

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, shared a post on LinkedIn by…

Feb 16, 2025, 10:56 | Blog

The Second Global OncoThon: Highlights Part 3

OncoDaily and the International Society of Pediatric Oncology (SIOP) are hosting the Second Global OncoThon, a 24-hour virtual event on February 15, 2025,…

Feb 12, 2025, 08:43 | Blog

Carmine Valenza: The evolution of malignant phyllodes tumors of the breast

Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared an article he…

Feb 3, 2025, 10:46 | Science

Paolo Cotzia: Tucatinib and trastuzumab with fulvestrant for HR+ patients in heavily pretreated HER2-mut MBC

Paolo Cotzia, Medical Director of Molecular Pathology and Head of Molecular Excellence at Sonic Healthcare…

Feb 1, 2025, 12:52 | Oncologist Near Me

Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research

Welcome to OncoDaily's special section “Oncologist Near Me” where we introduce prominent oncologists from around the world.…

Feb 1, 2025, 08:22 | Blog

Carmine Valenza, a member of the 2024-2025 PCE Outreach Team - Program in Clinical Effectiveness

Program in Clinical Effectiveness shared a post on LinkedIn: "Meet Carmine Valenza, a member of…

Jan 31, 2025, 07:23 | Blog

Giuseppe Curigliano: Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief, shared on X: "Adding nivolumab to…

Jan 29, 2025, 17:41 | Insight

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Enhertu (trastuzumab deruxtecan), developed by AstraZeneca and Daiichi Sankyo has been approved by The FDA…

Jan 28, 2025, 15:01 | Insight

Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X: "Check out the Breast Cancer Research Digest…

Jan 22, 2025, 18:49 | Insight

Breast Cancer Research Digest by Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X: “Here’s the most recent Breast Cancer…

Jan 20, 2025, 17:20 | Blog

Florian Lordick: Exploring the Pathway: New Insights in Gastrointestinal Oncology

Florian Lordick, Oncologist, Professor of Medicine at University of Leipzig, posted the following on LinkedIn:…

Jan 20, 2025, 13:34 | Blog

Great Debates and Updates in TNBC – Uniting Global Experts at BGICC 2025

BGICC-Breast Gynecological and Immunooncology International Cancer Conference shared a post on Facebook: "Great Debates and…

Jan 15, 2025, 17:48 | Insight

ESO announced the mentorship pairings for 2025

European School of Oncology (ESO) shared a post on Facebook: “We are pleased to announce…

Jan 14, 2025, 13:35 | Blog

Humaid Al-Shamsi: Two inspiring days with Giuseppe Curigliano at the European Institute of Oncology

Humaid Al-Shamsi, Founder and Director of Medical Oncology at Burjeel Medical City, posted on LinkedIn:…

Jan 11, 2025, 14:29 | Blog

Matthew Kurian: Highlights from San Antonio Breast Cancer Symposium 2024

Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine, shared…

Jan 5, 2025, 16:00 | Career

Giuseppe Curigliano: I have a new job position - ESMO President Elect

Giuseppe Curigliano, ESMO President-Elect and Open Editor in Chief shared a post on LinkedIn: "I…

Dec 22, 2024, 07:59 | Science

Ilana Schlam: The BRIDGES study is out

Ilana Schlam, Assistant Professor of Medicine at Tufts University Medical Center, shared on X about…

Dec 22, 2024, 05:00 | Blog

Elvina Almuradova: Being a part of Giuseppe Curigliano's team is an invaluable scientific milestone for me

Elvina Almuradova, Associate Professor at Medicana Health Group, shared a post on LinkedIn: "Being a…

Dec 21, 2024, 12:14 | Blog

Paolo Tarantino: Ending of a terrific 3-year cycle of PhD at The University of Milan

Paolo Tarantino, Research Fellow, Dana-Farber Cancer Institute, shared a post on LinkedIn: "Ending of a…

Dec 19, 2024, 16:53 | Blog

Giuseppe Curigliano: Great pleasure to host Prof. Humaid Al-Shamsi

Giuseppe Curigliano, Director of the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at…

Dec 13, 2024, 14:02 | Blog

Matthew Kurian: Day 2 at SABCS was one for the books

Matthew Kurian, Assistant Professor of medicine at the University of Kentucky College of Medicine, shared…

Dec 12, 2024, 16:50 | Insight

Imlunestrant and Abemaciclib: A Study in Advanced Breast Cancer

Imlunestrant has been approved for the treatment of breast cancer. It is a next-generation, brain-penetrant,…

Dec 12, 2024, 13:36 | Blog

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Erika Hamilton, The Director of Breast Cancer Program at Sarah Cannon Research Institute, shared on…

Dec 12, 2024, 13:26 | Insight

Highlights from Day 2 of SABCS 2024

The SABCS 2024 (San Antonio Breast Cancer Symposium) is taking place from December 10th to…

Dec 5, 2024, 17:04 | Insight

Khalid El Bairi: The growing concerns about the emergence of non-peer-reviewed journals in oncology

Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared a post on LinkedIn:…

Dec 5, 2024, 07:25 | Insight

Carmine Valenza: The Role of Germline BRCA Mutation in PARP Inhibitors-Related Hematologic Adverse Events

Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared a post on…

Dec 3, 2024, 13:09 | Insight

Khalid El Bairi: Our TASMAN study on the use of medical cannabis in oncology

Khalid El Bairi, Founder of The Cancer Biomarkers Working Group, shared a post on LinkedIn…

Nov 29, 2024, 19:46 | Insight

Evandro de Azambuja: Prevention of brain metastases in patients with HER2-positive breast cancer

Evandro de Azambuja, Director of Membership for the European Society for Medical Oncology (ESMO), shared…

Nov 29, 2024, 13:30 | Insight

Prevention of Brain Metastases HER2-positive Breast Cancer

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared a recent article by Volkmar…

Nov 29, 2024, 10:01 | Blog

Evandro de Azambuja: Improving ESMO's membership survey

Evandro de Azambuja, the Director of Membership for the European Society for Medical Oncology, posted…

Nov 22, 2024, 17:22 | Insight

Chiara Corti: Estrogen Signaling in Early-Stage Breast Cancer

Chiara Corti, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: “I am…

Nov 22, 2024, 16:51 | Blog

VHIO’s Josep Tabernero, Enriqueta Felip, and Ana Oaknin have been recognized as Clarivate Highly Cited 2024

Giuseppe Curigliano shared a post by Vall d’Hebron Institute of Oncology on X: "Congratulations Josep Tabernero , Enriqueta…

Nov 10, 2024, 13:41 | Blog

The most recent Breast Cancer Research Digest by Dana-Farber Cancer Institute

Dana-Farber’s Breast Oncology Center shared on X: "Check out the Breast Cancer Research Digest -…

Nov 4, 2024, 14:04 | Insight

Raffaele Colombo: Insights from October: Advances in ADC research and cancer therapeutics

Raffaele Colombo shared a post on LinkedIn: "October was extremely busy yet incredibly rewarding: With Jamie…

Nov 3, 2024, 15:49 | Blog

Paolo Cotzia: Investigating the role of immunotherapy in metastatic inflammatory breast cancer

Paolo Cotzia, Medical Director of Molecular Pathology and Head of Molecular Excellence at Sonic Healthcare…

Nov 2, 2024, 12:01 | Positive

Top 100 Xfluencers in Breast Cancer: Key Opinion Leaders to Follow on X (Twitter) in 2024

As Pink October has ended, it's time to reflect on Breast Cancer Awareness Month. OncoDaily…

Nov 2, 2024, 02:35 | Insight

Carmine Valenza: ICIs in patients with metastatic TN-IBC

Carmine Valenza, Medical Oncology Resident at the European Institute of Oncology, shared a post on…

Oct 30, 2024, 10:02 | Insight

Paper Alert ! Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer

Use of Antibody–Drug Conjugates in the Early Setting of Breast Cancer Authors: Chrysanthi Koukoutzeli, Dario…

Oct 29, 2024, 13:05 | Insight

Paolo Tarantino: My 100th scientific publication

Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X: "It turns out…

Oct 25, 2024, 11:41 | Blog

Raffaele Colombo: Honored to discuss ADCs at the ENASymp24

Raffaele Colombo shared a post by Sandra Misale, Assistant professor at Sidney Kimmel Comprehensive Cancer…

Oct 22, 2024, 14:33 | Blog

Sebastian Szmit: Risk stratification and long-term follow-up proposed by ESC guidelines on cardiooncology

Sebastian Szmit shared a post by Monika Majewska, Editor, journalist, conference moderator at Pulse of…

Oct 18, 2024, 12:10 | Blog

From One-Size-Fits-All to Personalized Treatment: An article by Marleen Kok et al.

Maryam Lustberg shared on LinkedIn: "From One-Size-Fits-All to Personalized Treatment: Challenges and Potential Solutions. Opportunities…

Oct 13, 2024, 17:58 | Blog

Raffaele Colombo: Excited to be presenting ADCs at the 36th ENA symposium

The 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics will be held in person…

Oct 10, 2024, 16:44 | Blog

Giuseppe Curigliano: With T-DXd for HR-Positive Metastatic Breast Cancer

Giuseppe Curigliano shared an article on X: "DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive…

Oct 9, 2024, 16:03 | OncoDaily Pulse

Inside OncoDaily Party Barcelona

On September 13, 2024, OncoDaily Party took place at the Chiringuito Mokai Beach Bar in Barcelona, Spain.…

Oct 7, 2024, 16:33 | Blog

Lika Katselashvili: Developing combination therapies with biologics in TNBC

Lika Katselashvili shared on X: "Incredibly grateful for the amazing experience at IEO Milano under…

Oct 6, 2024, 17:29 | Blog

Lizzy Smyth: Privileged to co-chair the first ESMO ADC Advanced Course with Giuseppe Curigliano

Lizzy Smyth shared a post on X by Alberto Puccini, adding: "What a privilege to…

Oct 5, 2024, 09:20 | Insight

DESTINY-Breast06 is the first study to investigate a HER2-directed therapy in patients with HER2-ultralow tumors - ASCO

ASCO shared a post on X: "Experts Giuseppe Curigliano & Aditya Bardia discuss the results of…

Oct 2, 2024, 15:37 | Blog

Zainab Shinkafi-Bagudu: Chairing Nigeria's Cancer Network to Address Survivors' Needs

Zainab Shinkafi-Bagudu shared a post on Linkedin: ''I take my role as Chair of the…

Sep 23, 2024, 11:36 | Blog

OncoDaily Party Barcelona

On September 13, 2024, OncoDaily Party took place at the Chiringuito Mokai Beach Bar in…

Sep 20, 2024, 23:18 | Blog

Yüksel Ürun: Key goals post ESMO24

Yüksel Ürun shared a post on LinkedIn: "Key goals post ESMO24 1.Integrate findings into practice…

Sep 19, 2024, 11:07 | Blog

Elias Ortega Chahla: ESMO - YO Mentorship Session

Elias Ortega Chahla, Medical Director (Hematology/Oncology), IQVIA, shared a post on LinkedIn: "ESMO - YO…

Sep 19, 2024, 09:29 | Insight

Guilherme Nader Marta: DESTINY-Breast06 trial out in The New England Journal of Medicine

Guilherme Nader Marta, Advanced Clinical Fellow - Dana-Farber Cancer Institute, shared a post on LinkedIn: "DESTINY-Breast06…

Sep 19, 2024, 09:19 | Blog

Taha Koray Sahin: Inspiring and valuable mentorship session at ESMO24

Taha Koray Sahin shared a post on X: "Big thanks to Giuseppe Curigliano for the insightful…

Sep 18, 2024, 12:21 | Blog

Andrea Botticelli: Presenting the Rome trial results at ESMO 24 Presidential Session

Andrea Botticelli posted on LinkedIn: "What a great emotion to present the Rome trial results at…

Sep 18, 2024, 09:18 | Insight

34 Posts Not to Miss From ESMO24 Day 4

The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…

Sep 18, 2024, 00:08 | Insight

Paolo Tarantino: Testing T-DXd vs chemo for endocrine-refractory HR+ MBC

Paolo Tarantino shared a post on X: "Previously presented at ASCO24 by Giuseppe Curigliano, the impressive…

Sep 1, 2024, 15:03 | Blog

ESMO is seeking a new Editor-in-Chief to ESMO Open

ESMO - European Society for Medical Oncology shared a post on LinkedIn: "ESMO is seeking…

Aug 31, 2024, 16:51 | Insight

Vivek Subbiah: Future framework for Tissue agnostic drug development

Vivek Subbiah shared a post on LinkedIn: "Hot off the press, Presenting to the world a…

Aug 26, 2024, 20:01 | Blog

EU HTA Cooperation on ECO Community 365 Roundtable series

European Cancer Organisation (ECO) shared a post on LinkedIn: “A landmark piece of EU legislation…

Aug 22, 2024, 03:05 | Insight

Jarushka Naidoo: Excited to be a part of the Swiss Oncology Summer School

Jarushka Naidoo shared on LinkedIn: “Excited to be a part of the Swiss Oncology Summer…

Aug 18, 2024, 13:43 | Insight

ECO Community 365 Roundtable: EU HTA Regulation

European Cancer Organisation shared on LinkedIn: “A landmark piece of EU legislation to achieve greater…

Aug 18, 2024, 07:29 | Blog,Opinion

Paolo Tarantino: Do all patients with TNBC need 5 neoadjuvant drugs + 1 year of IO?

Paolo Tarantino shared a post on X about recent paper by Marleen Kok et al., titled…

Aug 10, 2024, 05:56 | Blog

Natacha Bolaños and Giuseppe Curigliano discuss EU legislation on HTA - ECO

European Cancer Organisation (ECO) shared on LinkedIn: "Are we ready for Joint Clinical Assessments? On…

Aug 5, 2024, 01:55 | Societies

Scientific Committees at the ESMO Congress 2024

The ESMO Congress is a globally influential oncology platform that brings together clinicians, researchers, patient…

Jul 31, 2024, 03:46 | Blog

ECO Community 365 Roundtable: HTA Regulation

European Cancer Organisation posted on LinkedIn: "A landmark piece of European Union legislation to achieve…

Jul 30, 2024, 12:17 | Blog

María Natalia Gandur Quiroga: Highlights from the article 'Cancer survivorship at heart: a multidisciplinary cardio-oncology roadmap for healthcare professionals'

María Natalia Gandur Quiroga posted on LinkedIn about recent paper by Irma Bisceglia et al., titled…

Jul 27, 2024, 22:17 | Insight

Commentary led by Marleen Kok highlights all questions in early TNBC post-KN522

Erika Hamilton shared on X: "This commentary led by Marleen Kok highlights all the pertinent…

Jul 26, 2024, 00:03 | Blog

Elisa Agostinetto: Must-read by Marleen Kok on the limitations of KEYNOTE-522

Elisa Agostinetto shared on X: "Out in JCO a must-read by Marleen Kok on the…

Jul 25, 2024, 11:55 | Blog

European School of Oncology - The 2023 ESMO guidelines for early breast cancer diagnosis, treatment, and follow-up

European School of Oncology shared on LinkedIn: "Stay up-to-date with our e-Session 'The 2023 ESMO guidelines…

Jul 25, 2024, 08:58 | Insight

Marleen Kok: How do we get from one-size-fits-all to personalized treatment for TNBC

Marleen Kok, Breast Medical Oncologist at the Netherlands Cancer Institute, shared on X: "Today from…

Jul 25, 2024, 03:18 | Insight

6th and 7th ABC international consensus guidelines for the management of advanced breast cancer

ABC Global Alliance shared on LinkedIn: “Inequalities in access to care are a major hurdle…

Jul 24, 2024, 07:30 | Blog

European Union legislation on Health Technology Assessment - European Cancer Organisation

European Cancer Organisation shared a post on LinkedIn: ''A landmark piece of European Union legislation…

Jul 21, 2024, 10:33 | Blog

Filippo Montemurro: RWE of drug-drug interactions on abemaciclib

Filippo Montemurro, Senior Medical Director at F. Hoffmann La Roche, shared a post on X: "Clinical…

Jul 16, 2024, 05:54 | Blog

Unprecedented level of scientific discourse at INNOVATE

Hussein Tawbi, Professor at The University of Texas MD Anderson Cancer Center, shared a post…

Jul 15, 2024, 21:23 | Blog

Liz Burton: Humbling opportunity to co-chair the first International Neoadjuvant Immunotherapy Across Cancers in Naples

Liz Burton, Executive Director at UT MD Anderson Cancer Center, shared a post on X: …

Jul 15, 2024, 04:50 | Insight

Paolo Tarantino: Our article on ADCs is among the top 10 most cited in CA Cancer Journal

Paolo Tarantino, shared a post on LinkedIn about a recent paper titled "Antibody–drug conjugates: Smart…

Jul 6, 2024, 04:44 | Insight

The first meeting of our new Research Policy Network - ECO

European Cancer Organisation (ECO) shared on LinkedIn: “The first meeting of our new Research Policy…

Jul 3, 2024, 13:35 | OncoDaily Pulse

OncoDaily at ASCO 2024: OncoDaily Party, Yvonne Award and much more

OncoDaily at the Annual ASCO Conference 2024: A Comprehensive Report The American Society of Clinical…

Jul 3, 2024, 10:44 | Blog

Abeid M. Athman Omar: The last four months have been very eventful for me

Abeid M. Athman Omar, Clinical Oncology Specialist at Kenyatta University, shared a post on LinkedIn: "The last…

Jun 30, 2024, 10:58 | Insight

Eleonora Nicolò: Our analysis on safety and efficacy of new drugs investigated in phase I/II clinical trials by age

Eleonora Nicolò, Research Fellow at Weill Cornell Medicine, shared a post on X: "Just out…

Jun 25, 2024, 07:12 | Blog

Elisa Agostinetto and Giuseppe Curigliano discuss the results of Destiny-Breast06

Elisa Agostinetto shared on LinkedIn: "At ASCO24 I met Prof Giuseppe Curigliano to discuss the results…

Jun 22, 2024, 02:02 | Blog

Sameh Abdelmalak: Dr. Giuseppe Curigliano discussing ASCO24 DESTINY-Breast06

Sameh Abdelmalak, Director, Oncology, Educational Partnerships at VuMedi, made the following post on X: "Check out…

Jun 20, 2024, 16:05 | Insight

Eliz Tazimova: Our project at ESMO In Focus Breast Cancer 2024 Bulgaria

Eliz Tazimova, COO at Institute for Research of Breast Cancer Treatment, shared a post on…

Jun 19, 2024, 01:47 | Blog

ESO Congratulate Barbara Jereczek-Fossa and Giuseppe Curigliano On Being Elected Presidents of ESTRO and ESMO

European School of Oncology (ESO) shared a post on LinkedIn: . “The European School of…

Jun 15, 2024, 16:02 | Dialogues

Oncodaily Talks: Dialogue with Giuseppe Curigliano, hosted by Chandler Park

OncoDaily Talks gathers people worldwide to discuss challenges in cancer care. We share creative solutions…

Jun 15, 2024, 02:42 | Blog

Hesham El Ghazaly: Congrats Giuseppe Curigliano , joining as ESMO President-Elect 2025-2026

Giuseppe Curigliano shared a post by Hesham El Ghazaly, Professor of clinical Oncology at Ain Shams University,…

Jun 12, 2024, 15:37 | Societies

Giuseppe Curigliano has been appointed as the President Elect of ESMO

The European Society for Medical Oncology (ESMO) has announced the results of its presidential election.…

Jun 12, 2024, 09:57 | Blog

Giuseppe Curigliano will be the ESMO President 2027-2028

ESMO shared a post on LinkedIn: "ESMO is pleased to share the ESMO Presidential Election election…

Jun 10, 2024, 10:08 | Societies

Vivek Subbiah: I endorse Dr. Giuseppe Curigliano for ESMO President 2027-28

Vivek Subbiah shared on X: "The elections for the ESMO President 2027-2028 are happening, its…